Experimental Arm (arm A): atezolizumab plus bevacizumab and UCPVax
toxicity, telomerase-derived cancer
DISEASE PROGRESSION
UCPVax is a telomerase-derived cancer vaccine developed by academic research network at Besançon [The two UCPVax peptides: UCP2 and UCP4 at 0.5 mg/ml (combined with Montanide ISA51 as adjuvant), will be injected subcutaneously in two separate sites (one site per peptide) at days 1, 8, 15, 29, 36 and 43 (priming phase) following by boost vaccinations: every 6 weeks for the two first boosts (W13 and W19) and then every 9 weeks (W28, W37 and W46).In combination, patients will receive atezolizumab at fixed dose of 1200 mg in 60 min IV infusion and bevacizumab at fixed dose of 15 mg/kg in 90 min IV infusion since Day 1, every 3 weeks, until disease progression or unacceptable toxicity or maximum 2 years in according to standard of care (Fig. Treatment schedule in experimental armWhen the three drugs will be administrated in the same visit, atezolizumab will be administered first followed by bevacizumab, and then by UCPVax with a minimum of 5 min between dosing.